Cancer Treatment Stocks @Cancer-Med Smartportfolios

Cancer Treatment Stocks@Cancer-Med

Performance
0% Return
All

2025

2024

2023

2022

2021

2020

2019

2018

2017

55.9%0%-55.9%

Return YTD -0.25%

Return 2Y 43.4%

Avg. Risk Score (last 7D)

Profitable Weeks 60.00%

@Cancer-Med

Smart Portfolio

11 days ago

Dear Investors, Here is your monthly update for May 2025 ✨ Despite some volatility, stocks gained in May, driven by tech and AI momentum. Tariff deals and rate shifts boosted sentiment, while crypto hit new highs. Nvidia and Google led AI advances, and economic signals from the Fed, UK, and Middle... Show More

@Cancer-Med

Smart Portfolio

about a month ago

Dear Investors, Here is your monthly update for April 2025 ✨ April was marked by extreme market volatility, with stocks swinging sharply on tariff announcements and policy shifts. A surprise two-tier tariff plan from President Trump triggered a steep selloff, followed by a rapid recovery after he... Show More

@Cancer-Med

Smart Portfolio

2 months ago

Dear Investors, Here is your monthly update for March 2025 ✨ March was a rough month for markets, with most major indexes falling amid rising fears of tariffs, recession, and stagflation. President Trump’s sweeping tariff announcements, including 25% on autos, caused sharp market swings and left... Show More

@Cancer-Med

Smart Portfolio

4 months ago

Dear Investors, Here is your monthly update for February 2025 ✨ February was a mixed month for stocks, with US equities struggling while European and Chinese markets performed well. A major theme was capital shifting away from US tech stocks, with European indices hitting record highs and Chinese... Show More

@Cancer-Med

Smart Portfolio

4 months ago

Edited

💊 𝙀𝙡𝙞 𝙇𝙞𝙡𝙡𝙮 𝙒𝙖𝙣𝙩𝙨 𝙩𝙤 𝙐𝙨𝙚 𝙄𝙩𝙨 𝙒𝙚𝙞𝙜𝙝𝙩 𝙇𝙤𝙨𝙨 𝘿𝙧𝙪𝙜 𝙒𝙞𝙣𝙙𝙛𝙖𝙡𝙡 𝙩𝙤 𝙁𝙞𝙜𝙝𝙩 𝘼𝙡𝙯𝙝𝙚𝙞𝙢𝙚𝙧'𝙨 𝙖𝙣𝙙 𝙃𝙚𝙖𝙧𝙞𝙣𝙜 𝙇𝙤𝙨𝙨 $LLY (Eli Lilly & Co) (Eli Lilly & Co) is looking to leverage its success with weight loss drugs to fund groundbreaking treatments... Show More

Eli Lilly wants to use its weight loss drug windfall to fight Alzheimer's and hearing loss

finance.yahoo.com

The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the world. Now, the pharma giant wants to reinvest its success with weight-loss meds into tackling some of the world’s toughest health challenges.

@Cancer-Med

Smart Portfolio

4 months ago

Edited

Dear Investors, Here is your monthly update for January 2025 ✨ January was a strong month for stocks, with major indexes posting gains despite volatility in the AI sector. The rise of China’s DeepSeek AI app led to a tech sector selloff, causing Nvidia to lose $560 billion in market cap in one single... Show More

@Cancer-Med

Smart Portfolio

5 months ago

Edited

Dear Investors, happy new year! Here is your monthly update for December 2024 ✨ Following a robust rally in November, December delivered mixed market performance as concerns over rising bond yields and elevated valuations weighed on sentiment. Despite hitting new highs, the cryptoasset sector experienced... Show More

@Cancer-Med

Smart Portfolio

7 months ago

Dear Investors, Here is your monthly update for November 2024 ✨ November had a strong market performance in the US in the aftermath of Donald Trump's win in the US election. Investor sentiment improved after his victory, bringing the S&P 500 and Nasdaq-100 indexes to all-time highs. It was... Show More

@Cancer-Med

Smart Portfolio

7 months ago

Dear Investors, Here is your monthly update for October 2024 ✨ October featured several significant events that influenced markets both positively and negatively, including economic uncertainties, geopolitical tensions, corporate earnings, and the final lead-up to the U.S. election. Although equity... Show More

@Cancer-Med

Smart Portfolio

8 months ago

Dear Investors, Here is your monthly update for September 2024 ✨ September is usually challenging for global markets, but this year saw a strong reversal. The U.S. Federal Reserve cut interest rates by 50 basis points, leading to a significant rebound across most markets and pushing the S&P 500... Show More